keyword
MENU ▼
Read by QxMD icon Read
search

Lisa DeAngelis

keyword
https://www.readbyqxmd.com/read/29036697/the-elderly-left-behind-changes-in-survival-trends-of-primary-central-nervous-system-lymphoma-over-the-past-four-decades
#1
Joe S Mendez, Quinn T Ostrom, Haley Gittleman, Carol Kruchko, Lisa M DeAngelis, Jill S Barnholtz-Sloan, Christian Grommes
Background: There has been significant improvement in treatment outcomes of Primary Central Nervous System Lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population. Methods: In this study, we utilized two national databases to examine survival trends over time for PCNSL (Central Brain Tumor Registry of the United States (CBTRUS, 2000 - 2013) and 18 Surveillance, Epidemiology, and End Results (SEER, 1973 - 2013) registries)...
October 3, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29020536/novel-considerations-in-the-approach-to-glioblastoma
#2
Lauren R Schaff, Lisa M DeAngelis
No abstract text is available yet for this article.
October 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29019042/long-term-outcomes-of-adult-medulloblastoma-patients-treated-with-radiotherapy
#3
Brian De, Kathryn Beal, Kevin C De Braganca, Mark M Souweidane, Ira J Dunkel, Yasmin Khakoo, Stephen W Gilheeney, Lisa M DeAngelis, Paul Menzel, Suchit H Patel, Suzanne L Wolden
Medulloblastoma (MB) is rare in adults and treatment guidelines are consequently not well-established. Few modern series have reported long-term follow-up and treatment sequelae. We examined long-term outcomes of adult MB patients at one institution. Records of 29 consecutive patients (18 male, 11 female) aged ≥ 18 years who received radiotherapy (RT) for primary MB from 1990 to 2016 were reviewed. Median age at diagnosis was 28 years (range 18-72 years). Seventeen patients were standard risk and 12 were high risk...
October 10, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28988377/phase-i-study-of-sorafenib-and-tipifarnib-for-recurrent-glioblastoma-nabtc-05-02
#4
Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, Mark Gilbert, Lauren E Abrey, F Lieberman, Lisa M DeAngelis, H Ian Robins, W K Alfred Yung, Susan Chang, Jan Drappatz, Minesh P Mehta, Victor A Levin, Kenneth Aldape, Janet E Dancey, J J Wright, Michael Prados, John Kuhn, Timothy F Cloughesy
Recurrent glioblastoma (GBM) has a very low 6-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phase I study was to determine the maximum tolerated dose (MTD) for the combination of tipifarnib and sorafenib for the treatment of recurrent GBM. Patients with pathologically proven WHO grade IV GBM and radiographically proven tumor recurrence were eligible for this study...
October 7, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28926291/has-province-wide-symptom-screening-changed-opioid-prescribing-rates-in-older-patients-with-cancer
#5
Lisa Barbera, Rinku Sutradhar, Anna Chu, Hsien Seow, Craig C Earle, Mary Ann O'Brien, Deborah Dudgeon, Carlo DeAngelis, Clare Atzema, Amna Husain, Ying Liu, Doris Howell
PURPOSE: Previous work in Ontario demonstrated that 33% of patients with cancer with severe pain did not receive opioids at the time of their pain assessment. With efforts to increase symptom screening and management since then, the objective of this study was to examine temporal trends in opioid prescribing. METHODS: The cohort was comprised of Ontario residents ≥ 65 years of age with a cancer history who were eligible for the government pharmacare program and had a pain assessment using the Edmonton Symptom Assessment System...
September 19, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28870792/multicenter-phase-1-dose-escalation-study-of-hypofractionated-stereotactic-radiation-therapy-with-bevacizumab-for-recurrent-glioblastoma-and-anaplastic-astrocytoma
#6
Jennifer Clarke, Elizabeth Neil, Robert Terziev, Philip Gutin, Igor Barani, Thomas Kaley, Andrew B Lassman, Timothy A Chan, Josh Yamada, Lisa DeAngelis, Ase Ballangrud, Robert Young, Katherine S Panageas, Kathryn Beal, Antonio Omuro
PURPOSE: To establish the maximum tolerated dose of a 3-fraction hypofractionated stereotactic reirradiation schedule when delivered with concomitant bevacizumab to treat recurrent high-grade gliomas. METHODS AND MATERIALS: Patients with recurrent high-grade glioma with Karnofsky performance status ≥60, history of standard fractionated initial radiation, tumor volume at recurrence ≤40 cm(3), and absence of brainstem or corpus callosum involvement were eligible...
June 30, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28836029/increased-risk-of-arterial-thromboembolism-in-older-men-with-breast-cancer
#7
Anne S Reiner, Babak B Navi, Lisa M DeAngelis, Katherine S Panageas
PURPOSE: Male breast cancer is a rare and understudied disease predominantly affecting men over age 60. Risk of arterial thromboembolic events (ATE) in men increases with age. We examined ATE risk following primary breast cancer diagnosis in elderly men. METHODS: Men with primary breast cancer diagnoses from 2002 to 2011 were identified using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Cases were individually matched by age, sex, race, registry, and comorbidities with controls without cancer using SEER-Medicare's 5% noncancer sample...
August 23, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28821205/cerebrospinal-fluid-circulating-tumor-cells-a-novel-tool-to-diagnose-leptomeningeal-metastases-from-epithelial-tumors
#8
Xuling Lin, Martin Fleisher, Marc Rosenblum, Oscar Lin, Adrienne Boire, Samuel Briggs, Yevgeniya Bensman, Brenda Hurtado, Larisa Shagabayeva, Lisa M DeAngelis, Katherine S Panageas, Antonio Omuro, Elena I Pentsova
Background: Diagnosis of leptomeningeal metastasis (LM) remains challenging due to low sensitivity of CSF cytology and infrequent unequivocal MRI findings. In a previous pilot study, we showed that rare cell capture technology (RCCT) could be used to detect circulating tumor cells (CTC) in the CSF of patients with LM from epithelial tumors. To establish the diagnostic accuracy of CSF-CTC in the diagnosis of LM, we applied this technique in a distinct, larger cohort of patients. Methods: In this institutional review board-approved prospective study, patients with epithelial tumors and clinical suspicion of LM underwent CSF-CTC evaluation and standard MRI and CSF cytology examination...
September 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28818202/risk-of-arterial-thromboembolism-in-patients%C3%A2-with%C3%A2-cancer
#9
MULTICENTER STUDY
Babak B Navi, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin, Mitchell S V Elkind, Katherine S Panageas, Lisa M DeAngelis
BACKGROUND: The risk of arterial thromboembolism in patients with cancer is incompletely understood. OBJECTIVES: The authors aimed to better define this epidemiological relationship, including the effects of cancer stage. METHODS: Using the Surveillance Epidemiology and End Results-Medicare linked database, the authors identified patients with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011...
August 22, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28734882/opioid-prescribing-among-cancer-and-non-cancer-patients-time-trend-analysis-in-the-elderly-using-administrative-data
#10
Lisa Barbera, Rinku Sutradhar, Anna Chu, Hsien Seow, Doris Howell, Craig C Earle, Mary Ann O'Brien, Deb Dudgeon, Clare Atzema, Amna Husain, Ying Liu, Carlo DeAngelis
CONTEXT: In 2007, Cancer Care Ontario introduced a provincial symptom screening program, which included pain, for cancer patients. Over this same time, opioid prescribing has been increasingly scrutinized among non-cancer patients. The study purpose was to see if opioid prescribing changed among older adults after 2007 in the context of changing opioid regulations, and whether effects were different among patients with a cancer history. METHODS: Ontario residents aged ≥65 years were identified from 2004 to 2013...
July 20, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28650963/a-new-mechanistic-approach-for-the-further-development-of-a-population-with-established-size-bimodality
#11
Lisa Heermann, Donald L DeAngelis, Jost Borcherding
Usually, the origin of a within-cohort bimodal size distribution is assumed to be caused by initial size differences or by one discrete period of accelerated growth for one part of the population. The aim of this study was to determine if more continuous pathways exist allowing shifts from the small to the large fraction within a bimodal age-cohort. Therefore, a Eurasian perch population, which had already developed a bimodal size-distribution and had differential resource use of the two size-cohorts, was examined...
2017: PloS One
https://www.readbyqxmd.com/read/28647417/recurrent-thromboembolic-events-after-ischemic-stroke-in-patients-with-primary-brain-tumors
#12
Neal S Parikh, Jaclyn E Burch, Hooman Kamel, Lisa M DeAngelis, Babak B Navi
BACKGROUND: Stroke mechanisms and the risk of recurrent thromboembolism are incompletely understood in patients with primary brain tumors. We sought to better delineate these important clinical features. METHODS: We performed a retrospective cohort study of adults with primary brain tumors diagnosed with magnetic resonance imaging-confirmed acute ischemic stroke at the Memorial Sloan Kettering Cancer Center from 2005 to 2015. Study neurologists collected data on patients' cancer history, stroke risk factors, treatments, and outcomes...
October 2017: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/28645200/prognostic-awareness-prognostic-communication-and-cognitive-function-in-patients-with-malignant-glioma
#13
Eli L Diamond, Holly G Prigerson, Denise C Correa, Anne Reiner, Katherine Panageas, Maria Kryza-Lacombe, Justin Buthorn, Elizabeth C Neil, Alex M Miller, Lisa M DeAngelis, Allison J Applebaum
Background: Malignant glioma (MG) is a devastating neuro-oncologic disease with almost invariably poor prognosis. Prognostic awareness (PA) is the awareness of incurable disease and shortened life-expectancy (LE). Accurate PA is associated with favorable psychological outcomes at the end-of-life (EOL) for patients with cancer, however little is known about PA or prognostic communication in MG. Moreover, research has yet to evaluate the impact of cognitive impairment on PA and preferred forms of communication...
June 22, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28640701/primary-cns-lymphoma
#14
REVIEW
Christian Grommes, Lisa M DeAngelis
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during the last decades with the introduction of high-dose methotrexate. However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in the first-line setting...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28619981/ibrutinib-unmasks-critical-role-of-bruton-tyrosine-kinase-in-primary-cns-lymphoma
#15
Christian Grommes, Alessandro Pastore, Nicolaos Palaskas, Sarah S Tang, Carl Campos, Derrek Schartz, Paolo Codega, Donna Nichol, Owen Clark, Wan-Ying Hsieh, Dan Rohle, Marc Rosenblum, Agnes Viale, Viviane S Tabar, Cameron W Brennan, Igor T Gavrilovic, Thomas J Kaley, Craig P Nolan, Antonio Omuro, Elena Pentsova, Alissa A Thomas, Elina Tsyvkin, Ariela Noy, M Lia Palomba, Paul Hamlin, Craig S Sauter, Craig H Moskowitz, Julia Wolfe, Ahmet Dogan, Minhee Won, Jon Glass, Scott Peak, Enrico C Lallana, Vaios Hatzoglou, Anne S Reiner, Philip H Gutin, Jason T Huse, Katherine S Panageas, Thomas G Graeber, Nikolaus Schultz, Lisa M DeAngelis, Ingo K Mellinghoff
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown. We performed a phase I clinical trial with ibrutinib, the first-in-class BTK inhibitor, for patients with relapsed or refractory CNS lymphoma. Clinical responses to ibrutinib occurred in 10 of 13 (77%) patients with PCNSL, including five complete responses. The only PCNSL with complete ibrutinib resistance harbored a mutation within the coiled-coil domain of CARD11, a known ibrutinib resistance mechanism...
September 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28472509/multicenter-phase-ii-study-of-temozolomide-and-myeloablative-chemotherapy-with-autologous-stem-cell-transplant-for-newly-diagnosed-anaplastic-oligodendroglioma
#16
Alissa A Thomas, Lauren E Abrey, Robert Terziev, Jeffrey Raizer, Nina L Martinez, Peter Forsyth, Nina Paleologos, Matthew Matasar, Craig S Sauter, Craig Moskowitz, Stephen D Nimer, Lisa M DeAngelis, Thomas Kaley, Sean Grimm, David N Louis, J Gregory Cairncross, Katherine S Panageas, Samuel Briggs, Geraldine Faivre, Nimish A Mohile, Jayesh Mehta, Philip Jonsson, Debyani Chakravarty, Jianjiong Gao, Nikolaus Schultz, Cameron W Brennan, Jason T Huse, Antonio Omuro
Background: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods: Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day × 3 days, then busulfan 3...
October 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28453751/the-neurologic-assessment-in-neuro-oncology-nano-scale-a-tool-to-assess-neurologic-function-for-integration-into-the-response-assessment-in-neuro-oncology-rano-criteria
#17
Lakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, David M Peereboom, Evanthia Galanis, Nancy U Lin, Riccardo Soffietti, David R Macdonald, Marc Chamberlain, James Perry, Kurt Jaeckle, Minesh Mehta, Roger Stupp, Alona Muzikansky, Elena Pentsova, Timothy Cloughesy, Fabio M Iwamoto, Joerg-Christian Tonn, Michael A Vogelbaum, Patrick Y Wen, Martin J van den Bent, David A Reardon
Background.: The Macdonald criteria and the Response Assessment in Neuro-Oncology (RANO) criteria define radiologic parameters to classify therapeutic outcome among patients with malignant glioma and specify that clinical status must be incorporated and prioritized for overall assessment. But neither provides specific parameters to do so. We hypothesized that a standardized metric to measure neurologic function will permit more effective overall response assessment in neuro-oncology. Methods...
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28379471/reappraising-the-2016-who-classification-for-diffuse-glioma
#18
Andrew L Lin, Lisa M DeAngelis
No abstract text is available yet for this article.
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28153049/longitudinal-analysis-of-treatment-induced-genomic-alterations-in-gliomas
#19
E Zeynep Erson-Omay, Octavian Henegariu, S Bülent Omay, Akdes Serin Harmancı, Mark W Youngblood, Ketu Mishra-Gorur, Jie Li, Koray Özduman, Geneive Carrión-Grant, Victoria E Clark, Caner Çağlar, Mehmet Bakırcıoğlu, M Necmettin Pamir, Viviane Tabar, Alexander O Vortmeyer, Kaya Bilguvar, Katsuhito Yasuno, Lisa M DeAngelis, Joachim M Baehring, Jennifer Moliterno, Murat Günel
BACKGROUND: Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. METHODS: Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making...
February 2, 2017: Genome Medicine
https://www.readbyqxmd.com/read/28116649/phase-i-trial-of-aflibercept-vegf-trap-with-radiation-therapy-and-concomitant-and-adjuvant-temozolomide-in-patients-with-high-grade-gliomas
#20
Lakshmi Nayak, John de Groot, Jeffrey S Wefel, Timothy F Cloughesy, Frank Lieberman, Susan M Chang, Antonio Omuro, Jan Drappatz, Tracy T Batchelor, Lisa M DeAngelis, Mark R Gilbert, Kenneth D Aldape, Alfred W K Yung, Joy Fisher, Xiaobu Ye, Alice Chen, Stuart Grossman, Michael Prados, Patrick Y Wen
Anti-vascular endothelial growth factor (VEGF) therapy has shown promise in the treatment of high-grade gliomas (HGG). Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for VEGF-A, VEGF-B and placental growth factor, depleting circulating levels of these growth factors. The Adult Brain Tumor Consortium conducted a phase I trial of aflibercept and temozolomide (TMZ) in patients with newly diagnosed HGG with 2 dose levels and a 3+3 design. Three arms using aflibercept were examined; with radiation and concomitant temozolomide; with adjuvant temozolomide using the 5/28 regimen; and with adjuvant temozolomide using the 21/28 day regimen...
March 2017: Journal of Neuro-oncology
keyword
keyword
71962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"